METHODS: In this study, we collected urine samples from 30 patients with gallstones and 30 healthy controls. The urine samples were analysed using multi-omics platforms. Proteomics analysis was conducted using data-independent acquisition, whereas metabolomics analysis was performed using liquid chromatography-mass spectrometry (LC-MS).
RESULTS: Among the patients with gallstones, we identified 49 down-regulated and 185 up-regulated differentially expressed proteins as well as 195 up-regulated and 189 down-regulated differentially expressed metabolites. Six pathways were significantly enriched: glycosaminoglycan degradation, arginine and proline metabolism, histidine metabolism, pantothenate and coenzyme A biosynthesis, drug metabolism-other enzymes, and the pentose phosphate pathway. Notably, 10 differentially expressed proteins and metabolites showed excellent predictive performance and were selected as potential biomarkers.
CONCLUSIONS: The findings of our metabolomics and proteomics analyses provide new insights into novel biomarkers for patients with cholelithiasis in high-altitude areas.
方法:在本研究中,我们收集了30名胆结石患者和30名健康对照者的尿液样本。使用多组学平台分析尿样。蛋白质组学分析使用独立于数据的采集进行,而代谢组学分析使用液相色谱-质谱(LC-MS)进行.
结果:在胆结石患者中,我们鉴定出49种下调和185种上调的差异表达蛋白,以及195种上调和189种下调的差异表达代谢物.六个途径显著富集:糖胺聚糖降解,精氨酸和脯氨酸代谢,组氨酸代谢,泛酸和辅酶A的生物合成,药物代谢-其他酶,和磷酸戊糖途径。值得注意的是,10种差异表达的蛋白质和代谢物显示出优异的预测性能并被选为潜在的生物标志物。
结论:我们的代谢组学和蛋白质组学分析结果为高海拔地区胆石症患者的新型生物标志物提供了新的见解。